

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David B. Agus Examiner: Rebecca Cook

Serial No.: 10/625,152 Group Art Unit: 1614

Filed: July 23, 2003 Docket: 67789-19

Title: USE OF BENZOTHIOPENES TO TREAT AND PREVENT PROSTATE

CANCER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicant has included the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 04-0258.

The Examiner is invited to contact the Applicant's Representative at the belowlisted telephone number if there are any questions regarding this communication.

In accordance with the Patent and Trademark Office's waiver of the requirement under 37 C.F.R.§ 1.98(a)(2)(i), copies of the listed U.S. patents are not enclosed because the current application has been filed after June 30, 2003.

Title: USE OF BENZOTHIOPENES TO TREAT AND PREVENT PROSTATE CANCER

In accordance with the waiver of 37 C.F.R.§ 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and publication for all U.S. national patent applications filed after June 30, 2003, only copies of the foreign references and other documents are enclosed.

July 7, 2005

Respectfully submitted, DAVIS WRIGHT TREMAINE LLP

Registration No. 44,869

865 South Figueroa Street

Suite 2400

Phone: (213) 633-6869 Facsimile: (213) 633-6899

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 7th day of July, 2005.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE	Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/625,152	
OVE	Filing Date	July 23, 2003	
1005	First Named Inventor	Agus, David	
JUL 1,1 2005 H	Group Art Unit	Unknown	
RADEMARK	Examiner Name	Unknown	
Sheet 1 of 1	Attorney Docket No: 67	7789-019	

US PATENT DOCUMENTS					
Exami ner Initial *	Cit e No.	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines,Wh ere Relevant Passages or Relevant Figures Appear
		US- 2003/0158164	08/21/2003	Ohta, et al.	
		US- 2004/0002484A1	01/01/2004	Hanson, et al.	
		US- 2004/0142973	07/22/2004	Castle	
		US-4,133,814	01/09/1979	Jones, et al.	
		US-5,135,849	08/04/1992	Soto, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. *	Foreign Document No Country Code – Number –	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines, Where Relevant Passages or Relevant	T²
		Kind Code (if known)	0.4/4.0/0.004	11 11 1 1 1	Figures Appear	
		WO- 01/27129 A1	04/19/2001	Holick, et al.		

	0	THER DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No 1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		DIAZ, MICHAEL, et al., "Management of Androgen-Independent Prostate Cancer", Cancer Control, Vol. 11, No. 6 (2004) pp. 364-373	
		KIM, ISAAC Y., et al., "Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis in Androgen-independent Human Prostate Cancer Cell Lines", <i>Cancer Research</i> 62(18) (Sept. 15, 2002) pp. 5365-5369	